The majority of cryptoglandular fistula-in-ano were treated by primary fistulotomy or staged fistulotomy with a loose seton. This was associated with a low recurrence rate and low rates of faecal incontinence. There was a low reliance on imaging techniques in this group. However, we would urge caution when dealing with fistula-in-ano related to Crohn's disease. In this group of patients, the fistulae tended to be more complex and require additional imaging and multiple procedures.

Streptococcus dysgalactiae has two main subspecies: Streptococcus dysgalactiae subsp. equisimilus (SDSE) and Streptococcus dysgalactiae subsp. dysgalactiae (SDSD). The vast majority of human infections belonging to Streptococcus dysgalactiae have been associated with SDSE. There are only three cases of SDSD found in humans in literature. We present a case of SDSD cellulitis and bacteremia in a 49-year-old female patient from Houston, Texas with no major exposure to animals or trauma.

IntroductionCOVID-19 is an ongoing pandemic that has lasted more than a year. Patients with multiple comorbidities such as diabetes, hypertension, and smoking have been shown to be at increased risk of a more severe course and lethal outcome. Since the disease can also lead to a hypercoagulable state, several cases of acute myocardial infarction (AMI) have also been recorded.Material and methodsWe searched PubMed/Medline for case reports of AMI occurring in COVID-19 positive patients using “acute myocardial infarction”, “COVID-19”, and “SARS-CoV-2” as keywords.ResultsThirty-three articles covering 37 patients were identified, among which 30 (81.1%) were male, and 7 (18.9%) were females. The mean age of these 37 patients was 52.8 ±15.6 years. Most cases were from the United States (17 cases, 45.9%). Several comorbidities such as hypertension (16 cases, 43.2%), diabetes (14 cases, 37.8%), smoking (8 cases, 21.6%), obesity (3 cases, 8.1%), morbid obesity (1 case, 2.7%), and elevated lipid levels (4 cases, 10.8%) were also identified. The most common symptom of AMI was chest tightness (22 cases, 59.5%), while the most common symptoms for COVID-19 were dyspnoea (25 cases, 67.6%) and fever (22 cases, 59.5%). The mortality rate was 35.1%.ConclusionsGiven the high mortality rate, physicians are encouraged to properly check for signs of cardiac dysfunction and possible AMI while treating COVID-19 positive patients with several comorbidities or previous history of AMI.

Nipah virus (NiV) is a deadly virus with a high mortality rate that has affected many developing countries in the past. According to the Centers for Disease Control and Prevention (CDC), many economically deprived countries such as Madagascar, Cambodia, and Thailand are also at high risk for future outbreaks. The first case of NiV was reported in 1998 and almost two decades later, little scientific progress has been made in finding a proper treatment and prevention vaccine. As many developing countries are not properly equipped to fight the infection, it is vital to properly educate the health systems. The aim of this review is to provide an epidemiological background as well as to understand the transmission routes, presentation, and the diagnosis and prevention of this deadly virus.

It has been more than a year since the new virus called severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China. The disease it causes was named Coronavirus disease 2019 (COVID-19), and on 11 March 2020 it was declared a pandemic. As the virus continues to spread, the number of patients worldwide has already crossed the 100 million mark with more than 2 million deaths. We sought to provide an update on the progress made in identifying the virus, its pathophysiology, risk factors such as hypertension, diabetes, and smoking, as well as various methods of treatment. Our review also provided an overview of the different vaccines.